Laboratory Corporation of America Holdings
NYSE: LH · HEALTHCARE · DIAGNOSTICS & RESEARCH
Updated 2026-04-29
Laboratory Corporation of America Holdings (LH) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for LH.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
LH historical valuation range
Where current P/E sits in LH's own 5Y range.
LH intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
LH valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 24.56x
P/S Ratio — History
Current: 1.52x
Is LH overvalued in 2026?
Laboratory Corporation of America Holdings (LH) currently trades at $257.14 per share with a market capitalization of $21,188,338,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 63/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 24.6x, below its 5-year median of 25.2x. The PEG ratio of 1.06 points to a price that reasonably reflects expected earnings growth.
Looking at its own history, LH is currently trading cheaper than 56% of the last 5Y on P/E. This places it in the 44th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates LH's intrinsic value at $314.31 per share, against the current market price of $257.14. This implies a margin of safety of +7.77%. The stock is priced close to its estimated fair value, offering limited upside without further operational improvement.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: LH trades at a fair valuation on our framework, with a Smart Value Score of 63/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is LH overvalued in 2026?
Based on a Smart Value Score of 63/100, LH is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is LH's fair value?
Our DCF model estimates LH's intrinsic value at $314.31 per share, versus the current price of $257.14. This produces a margin of safety of +7.77%.
What P/E ratio does LH trade at?
LH trades at a P/E of 24.6x on trailing twelve-month earnings, compared to its 5-year median of 25.2x.
Is LH a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 63/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does LH's valuation compare to its history?
On P/E, LH currently sits in the 44th percentile of its own 5Y range. That is below its long-run median relative to where it has traded over the period.
What is LH's Smart Value Score?
LH's Smart Value Score is 63/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.